My primary focus has been Evenity and Prolia since this was the route of my planned treatment which has been reset. Amgen chooses to use the Relative Risk Reduction to overstate the efficacy. For example, according to Amgen, studies on fracture risk in women taking Evenity has an Absolute Risk Reduction of 1,3% and an RRR 73%. Amgen chooses to market the 73% RRR making it sound as though the drug reduced reduction of spinal fractures by 73% when the drug has truly an ARR of 1.3% (dropping from 1.8% to .5%). That minimal absolute reduction in fractures is hardly worth taking a drug with such potential brutal side effects. And because Evenity is so new…who knows what the long term effects of this drug are other than what Amgen has already stated that you could have atypical femur fractures, osteonecrosis of the jaw or an increased risk of death from cardiac events. Perhaps other drug developers use the same overstatement of benefits; however, I have not reviewed them. When I agreed to Evenity, the 73% RRR sounded amazing. After my awful experience with my first injections, I dug deeper. Take a look at the Evenity website. It states “Proven to reduce spine fracture risk by 73%.” In much smaller print below this claim, it explains the actual ARR position “women receiving Evenity had fewer new spine fractures (0.5%) than women receiving placebo (1.8%).” Take a few moments to familiarize yourself with RRR and ARR. Interesting info!